1477 Results

People

  1. Motzer
    Motzer
  2. Hudis
    Hudis
  3. Aghajanian
    Aghajanian
  4. O'Reilly
    O'Reilly
  5. Kris
    Kris
  6. Scher
    Scher
  7. Panageas
    Panageas
  8. Saltz
    Saltz
  9. Schwartz
    Schwartz
  10. Kelsen
    Kelsen

Groups

  1. Department of Medicine (1039)
  2. Solid Tumor Oncology Division (784)
  3. Hematologic Malignancies, Division of (287)
  4. Survivorship Research (234)
  5. Center for Hematologic Malignancies (216)
  6. Genitourinary Oncology Service (208)
  7. Epidemiology and Biostatistics (194)
  8. Biostatistics Service (169)
  9. Gastrointestinal Oncology Service (160)
  10. Population Sciences Research Program (158)
  1. "fatigue"
Formats
  1. Journal Article (1402)
  2. Review (38)
  3. Research Letter (13)
  4. Editorial (10)
  5. Conference Paper (5)
  6. Guidelines (4)
  7. Correspondence (3)
  8. Book Section (2)
Groups
  1. Department of Medicine (1039)
  2. Solid Tumor Oncology Division (784)
  3. Hematologic Malignancies, Division of (287)
  4. Survivorship Research (234)
  5. Center for Hematologic Malignancies (216)
  6. Genitourinary Oncology Service (208)

More Groups

People
  1. Robert Motzer (85)
  2. Clifford Hudis (49)
  3. Carol Aghajanian (46)
  4. Eileen O'Reilly (46)
  5. Howard Scher (44)
  6. Mark Kris (44)

More People

Years
  1. 2025 (60)
  2. 2024 (132)
  3. 2023 (89)
  4. 2022 (46)
  5. 2021 (33)
  6. 2020 (85)

More Years

Publications
  1. Journal of Clinical Oncology (108)
  2. Clinical Cancer Research (82)
  3. Cancer (63)
  4. Lancet Oncology (50)
  5. Gynecologic Oncology (41)
  6. Annals of Oncology (37)

More Publications

Publishers
  1. Elsevier Inc. (244)
  2. Springer (133)
  3. American Society of Clinical Oncology (114)
  4. Elsevier Science, Inc. (108)
  5. Oxford University Press (101)
  6. American Association for Cancer Research (89)

More Publishers

Results (1477)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study
    Journal Article

    Rubinstein, M. M.; Doria, E. R.; Konner, J.; Lichtman, S.; Zhou, Q.; Iasonos, A.; Sarasohn, D.; Troso-Sandoval, T.; Friedman, C.; O'Cearbhaill, R.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Association of baseline self-reported fatigue with overall survival after stereotactic body radiation therapy for localized prostate cancer
    Journal Article

    Simhal, R. K.; Sholklapper, T. N.; Simhal, A. K.; Zwart, A. L.; Danner, M. T.; Kumar, D.; Aghdam, N.; Suy, S.; Hankins, R. A.; Kowalczyk, K. J.; more...
    Frontiers in Oncology (2022)

    Fulltext@MSK | Save
  • Successful brentuximab vedotin and nivolumab therapy of multiply refractory diffuse large B-cell lymphoma with Hodgkin features
    Correspondence

    Zibara, V.; Sen, F.; Scordo, M.; Falchi, L.
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: A phase II risk-adapted design
    Journal Article

    Kumar, A.; Casulo, C.; Joffe, E.; Moskowitz, C.; Gerecitano, J.; Moskowitz, A.; Younes, A.; Drullinsky, P.; Drill, E.; Choma, M.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Stereotactic magnetic resonance-guided adaptive radiation therapy (SMART) for abdominopelvic oligometastases
    Journal Article

    Yang, D. D.; Brennan, V. S.; Huynh, E.; Williams, C. L.; Han, Z.; Ampofo, N.; Vastola, M. E.; Sangal, P.; Singer, L.; Mak, R. H.; more...
    International Journal of Radiation Oncology, Biology, Physics (2022)

    Fulltext@MSK | Save
  • Neo-adjuvant FOLFIRINOX in borderline resectable and locally advanced pancreatic adenocarcinoma
    Journal Article

    Temraz, S.; Nassar, F.; Hammoud, M. S.; Mukherji, D.; O'Reilly, E. M.; Dbouk, H.; Farhat, F.; Charafeddine, M.; Faraj, W.; Khalifeh, M. J.; more...
    Asia-Pacific Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT)
    Journal Article

    Sella, T.; Zheng, Y.; Tayob, N.; Ruddy, K. J.; Freedman, R. A.; Dang, C.; Yardley, D.; Isakoff, S. J.; Valero, V.; DeMeo, M.; more...
    npj Breast Cancer (2022)

    Fulltext@MSK | Save
  • Levoketoconazole treatment in endogenous Cushing’s syndrome: Extended evaluation of clinical, biochemical, and radiologic outcomes
    Journal Article

    Fleseriu, M.; Auchus, R. J.; Greenman, Y.; Zacharieva, S.; Geer, E. B.; Salvatori, R.; Pivonello, R.; Feldt-Rasmussen, U.; Kennedy, L.; Buchfelder, M.; more...
    European Journal of Endocrinology (2022)

    Fulltext@MSK | Save
  • Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer
    Journal Article

    Van Cutsem, E.; Hochster, H.; Shitara, K.; Mayer, R.; Ohtsu, A.; Falcone, A.; Yoshino, T.; Doi, T.; Ilson, D. H.; Arkenau, H. T.; more...
    ESMO Open (2022)

    Fulltext@MSK | Save
  • Ixazomib and dexamethasone in high risk smoldering multiple myeloma: A clinical and correlative pilot study
    Correspondence

    Mailankody, S.; Salcedo, M.; Tavitian, E.; Burge, M.; Korde, N.; Hassoun, H.; Lesokhin, A.; Lahoud, O.; Smith, E.; Hultcrantz, M.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save